Copy

 

In the months of August & September 2021, we are focusing our campaign on swine diseases. Diseases such as African Swine Fever and Porcine Cysticercosis are responsible for significant economic losses. Porcine Cysticercosis can cause epileptic seizures in humans.  In the past, GALVmed has supported the testing and commercial development of a vaccine, based on technology from the University of Melbourne, which became the first licensed cysticercosis vaccine for pigs. This work has produced some lessons as documented in the featured publication below. Our work on ASF continues and you can learn more about what we are doing in this area. 

Photo by Michel Dione/ILRI

More on our swine programmes

Porcine Cysticercosis Vaccine Market Scoping:
Lessons learnt from the Uganda smallholder pigs value chains  

GALVmed commissioned this market scoping study to assess the potential demand for the TSOL vaccine-oxfendazole combination and to gain a clear understanding of its potential for ‘private good’ marketing. The study also assessed how the vaccine might influence product availability, supply mechanisms, price structure, competitiveness of products, profit margins, and the potential to sell these products to smallholder pig producers in Uganda.

Photo by Michel Dione/ILRI

Download the publication

Of pigs and People: The battle to break the cycle of Neurocysticercosis 

Porcine Cysticercosis is a serious zoonotic disease prevalent in many parts of the world especially in developing countries, where sanitation remains a challenge. It causes 30% of human epilepsy cases in the developing world. Controlling Porcine Cysticercosis in pigs can break the cycle of infection to humans.

GALVmed appoints new Senior Director of Research & Development 

GALVmed is pleased to announce the appointment of Dr Johnson Ouma as the new Senior Director of Research & Development, effective October 11, 2021. Dr Ouma is a Kenyan research & development professional with over 25 years’ experience in animal health and agricultural research & product development.

Learn more about our new R&D Director
G20: Invest in animal health, or risk undermining global health

75% of all new human infections emerge from animals. These zoonotic diseases, like COVID-19, and growing anti-microbial resistance are a huge risk to global health and economic recovery. This means the need to embrace a One Health approach has never been more urgent. As the G20 Health Ministers meeting approaches, the Action for Animal Health Coalition urges G20 countries to support four transformative actions for stronger animal health systems. 
Read more

Here are some of our recent publications

Our sincere appreciation to those who to took part in our Communications and Engagement survey. Your valuable input will go a long way in improving our engagement with you. Thank you.
Follow us on social media
GALVmed's Facebook
GALVmed's Twitter
Link
LinkedIn
YouTube
Copyright © 2021 GALVmed, All rights reserved.

Our mailing address is:
GALVmed
Doherty Building, Pentlands Science Park
Bush Loan
Edinburgh, Mln EH26 0PZ
United Kingdom

Add us to your address book


Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp